Active Surveillance Prostate Cancer Video Chat, June 10th, 2026
AnCan is grateful to the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics, Telix, and Foundation Medicine.
Active Surveillance (AS) for low-risk prostate cancer involves unique challenges compared to other treatments. This online support group is designed for men and their caregivers who are currently on or considering AS. We hold four meetings monthly, recording only the second and fourth sessions. Our discussions cover a wide range of topics, including anxiety management, biopsy experiences, and the decision-making process around continuing or discontinuing AS. Newcomers are given priority to share their experiences, so we encourage you to join us.
You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/. Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/.
Andy Douglas, Florida 8:11 PM
Jonathan Epstein, MD
Andy Douglas, Florida 8:11 PM
Advanced Uropathology of New York 700 Stewart Ave, Suite 101 Garden City, NY 11530 Hours: Monday-Friday 9:00AM – 6:00PM P: 516-760-2037 F: 516-200-3899 jepstein@imppllc.com
Ray E 8:12 PM
Ming Zhou Md
Ray E 8:12 PM
https://profiles.mountsinai.org/ming-zhou
Andy Douglas, Florida 8:23 PM
Shaw Zhou, MD St Petersburg 38th Avenue 5747 38th Ave N, St. Petersburg, Florida 33710 Phone (727) 381-8667
Ed Cirimele, Ca 8:39 PM
Ed Cirimele: jocimo@gmail.com
Eric 8:41 PM
Gotta head back to it. Thanks!
Andy Douglas, Florida 8:43 PM
https://www.healthcare6.com/physician/san-rafael-ca/joseph-lee-2179445.html
AnCan – Rick 8:45 PM
Here’s the KP link Ed…. https://mydoctor.kaiserpermanente.org/ncal/providers/jhlee
Andy Douglas, Florida 8:49 PM
PSA density is a measure that relates the level of prostate-specific antigen (PSA) in the blood to the size of the prostate gland, calculated by dividing the PSA value by the prostate volume. A higher PSA density can indicate a greater risk of prostate cancer, especially if it is above 0.15 ng/mL/cc.
Active Surveillance Prostate Cancer Video Chat, May 27th, 2026
AnCan is grateful to the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics, and Foundation Medicine.
Active Surveillance (AS) for low-risk prostate cancer involves unique challenges compared to other treatments. This online support group is designed for men and their caregivers who are currently on or considering AS. We hold four meetings monthly, recording only the second and fourth sessions. Our discussions cover a wide range of topics, including anxiety management, biopsy experiences, and the decision-making process around continuing or discontinuing AS. Newcomers are given priority to share their experiences, so we encourage you to join us.
Eric- Atlanta 8:18 PM
2nd Opinin for Biopsy links: https://ancan.org/prostate-cancer-and-gu-pathology-2nd-opinions/
Eric- Atlanta 8:22 PM
The Active Surveillor: https://howardwolinsky.substack.com
Eric- Atlanta 8:32 PM
New Prostate Cancer Guidelines and ASPI Pathway: https://ancan.org/new-prostate-cancer-guidelines-and-aspi-pathway/
Eric- Atlanta 8:39 PM
Ancan Solo Arts Heal: https://ancan.org/solo-arts-heal/ Tonight at 10:30EST
AnCan – Rick 8:52 PM
Here’s another more direct link if you’d like to listen to Laurie and myself. https://themarsh.org/soloartsheal/
Eric- Atlanta 8:53 PM
‘Threading the Clinical Needle’ on Gleason 6/GG1: A Matter of Language and Math: https://howardwolinsky.substack.com/p/threading-the-clinical-needle-on
Joe C 9:14 PM
Thanks, guys. Appreciate the discussion, information and all the good advice. I have to drop.
AnCan – Rick 9:25 PM
Cipro is the standard GU antibiotic
AnCan – Rick 9:28 PM
Gotta run over for the Solo Arts Heal tech check. Please join us at 7.30 pm Pacific https://themarsh.org/soloartsheal/ Good night, Gents…
A relatively new year, new guidelines, and new tools for prostate cancer screening and monitoring.
In recent months, the AUA updated its 2023 guidelines specifically for early detection of prostate cancer (https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guideline). Along with those guidelines, two other organizations have updated or developed additional tools that are beneficial to all men, regardless of where they are on the prostate cancer journey (or even those not yet on a journey).
Consider them collectively as an introduction to screening (NCCN), an AS-focused source (ASPI), and a comprehensive guide for early-stage prostate cancer.
I would not consider any of them as a standalone product for all the information a man might need. The NCCN guidelines are focused on screening and are relatively basic. ASPI’s product is focused on AS, but some may find the scope and scale of information a bit overwhelming without someone to advise and assist them. The appendix at the end of the pamphlet would be exceedingly useful for anyone beginning their prostate cancer journey. Finally, the AUA guidelines are broader and developed more for urologists.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer.
——————————————————————————————————–
2nd Thursday of each month at 8 pm Eastern in The Barniskis Room (222-583-973)
AnCan frequently recommends second opinions on prostate cancer and genitourinary (GU) pathology slides – whether it be from biopsy, surgery or another protocol. Our recommended providers are:
